Literature DB >> 1355767

Dexamethasone selectively regulates the activity of enzymatic markers of cerebral endothelial cell lines.

L Juillerat-Jeanneret1, A Aguzzi, O D Wiestler, P Darekar, R C Janzer.   

Abstract

Two endothelial cell lines were derived from grafts of the central nervous system using retrovirus mediated gene transfer to introduce the polyoma middle-T oncogene into fetal rat brain endothelial cells and transplantation of these cells into adult rat brain. In this report, we further characterize these cells and the effect of dexamethasone on the expression of specific enzymatic markers. These cells take up acetylated low density lipoprotein, leucine, and glucose, and express Factor VIII-related antigen, angiotensin converting enzyme, alkaline phosphatase, gamma-glutamyltranspeptidase, and as yet undescribed aminopeptidase A and B-like enzymes. When grown on semi-permeable membranes, these transformed cells do not spontaneously retain small hydrophilic molecules. In culture, one of the lines (EC 193) forms a confluent monolayer of spindle-shaped cells homogenously expressing gamma-glutamyltranspeptidase at a level comparable to primary cells. The other cell line (EC 219) grows as clusters of elongated cells, and gamma-glutamyltranspeptidase activity is expressed mainly in cells forming the clusters. This clustered pattern changes to a confluent one after culture on type-I collagen. Dexamethasone increases angiotensin-converting enzyme activity, and decreases the expression of gamma-glutamyltranspeptidase and aminopeptidase A, whereas the aminopeptidase B activity is little modified. Inhibition of aminopeptidase A activity by amastatin, potentiates angiotensin II effects on DNA synthesis. These results indicate that retrovirally transformed brain endothelial cells are a useful model for studying the blood-brain barrier in vitro and that dexamethasone, an agent with the potential to reduce brain edema, directly affects some blood-brain barrier properties in these endothelial cell lines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355767     DOI: 10.1007/bf02634138

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  37 in total

1.  The brain-type glucose transporter mRNA is specifically expressed at the blood-brain barrier.

Authors:  R J Boado; W M Pardridge
Journal:  Biochem Biophys Res Commun       Date:  1990-01-15       Impact factor: 3.575

2.  Endothelial cell tumors develop in transgenic mice carrying polyoma virus middle T oncogene.

Authors:  V L Bautch; S Toda; J A Hassell; D Hanahan
Journal:  Cell       Date:  1987-11-20       Impact factor: 41.582

3.  Permeability characteristics of cultured endothelial cell monolayers.

Authors:  S M Albelda; P M Sampson; F R Haselton; J M McNiff; S N Mueller; S K Williams; A P Fishman; E M Levine
Journal:  J Appl Physiol (1985)       Date:  1988-01

4.  Electrical resistance and macromolecular permeability of brain endothelial monolayer cultures.

Authors:  M J Rutten; R L Hoover; M J Karnovsky
Journal:  Brain Res       Date:  1987-11-10       Impact factor: 3.252

5.  Characteristics of aminopeptidase activity from bovine brain microvessel endothelium.

Authors:  A Baranczyk-Kuzma; K L Audus
Journal:  J Cereb Blood Flow Metab       Date:  1987-12       Impact factor: 6.200

6.  Astrocytes induce blood-brain barrier properties in endothelial cells.

Authors:  R C Janzer; M C Raff
Journal:  Nature       Date:  1987 Jan 15-21       Impact factor: 49.962

7.  Stimulation of glucose analogue uptake by cerebral microvessel endothelial cells by a product released by astrocytes.

Authors:  K Maxwell; J A Berliner; P A Cancilla
Journal:  J Neuropathol Exp Neurol       Date:  1989-01       Impact factor: 3.685

8.  gamma-Glutamyl transpeptidase from kidney.

Authors:  S S Tate; A Meister
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

9.  Determinants of angiotensin II generation during converting enzyme inhibition.

Authors:  L Juillerat; J Nussberger; J Ménard; V Mooser; Y Christen; B Waeber; P Graf; H R Brunner
Journal:  Hypertension       Date:  1990-11       Impact factor: 10.190

10.  Regulation of angiotensin converting enzyme.

Authors:  F Fyhrquist; C Grönhagen-Riska; L Hortling; T Forslund; I Tikkanen
Journal:  J Hypertens Suppl       Date:  1983-10
View more
  6 in total

1.  Evaluation of the interaction between TGF beta and nitric oxide in the mechanisms of progression of colon carcinoma.

Authors:  Sylvia Lohm; Lucie Peduto-Eberl; Patricia Lagadec; Nicole Renggli-Zulliger; Jean Dudler; Jean-François Jeannin; Lucienne Juillerat-Jeanneret
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 2.  The blood-brain barrier: cellular basis.

Authors:  R C Janzer
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

3.  Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-beta1 in tumor cells. Implications for tumor development.

Authors:  P Lagadec; S Raynal; B Lieubeau; N Onier; L Arnould; V Saint-Giorgio; D A Lawrence; J F Jeannin
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

4.  Pneumococcal trafficking across the blood-brain barrier. Molecular analysis of a novel bidirectional pathway.

Authors:  A Ring; J N Weiser; E I Tuomanen
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

5.  Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme).

Authors:  L Juillerat-Jeanneret; J D Aubert; P Leuenberger
Journal:  J Lab Clin Med       Date:  1997-12

6.  Differential Effects of the Mitochondria-Active Tetrapeptide SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2) and Its Peptidase-Targeted Prodrugs in Experimental Acute Kidney Injury.

Authors:  Jean-Christophe Wyss; Rajesh Kumar; Josip Mikulic; Manfred Schneider; Jean-Luc Mary; Johannes D Aebi; Lucienne Juillerat-Jeanneret; Dela Golshayan
Journal:  Front Pharmacol       Date:  2019-11-08       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.